GVK BIO Completes Drug Repurposing Efforts for Takeda

GVK Biosciences has successfully completed in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Co. Ltd. using its Drug Repurposing Platform. GVK BIO and Takeda have jointly agreed to evaluate the preclinical proof-of-concept for certain indications of selected therapeutic compounds to develop new indications for the previously failed compounds.
 
GVK BIO’s Drug Repurposing Platform, GRIP (GVK BIO Repurposing Integrated Platform), is a combination of proprietary repurposing database, eight different repurposing algorithms, analytics tools and visualization engine.
 
The repurposing database comprises more than 45 databases that enable the relationship between Drug-Target-Disease, and repurposing algorithms allow for unbiased interpretation of the data to predict alternative indications. GVK BIO also offers in-silico analysis and preclinical support to execute projects and establish proof of concept.
 
Nandu Gattu, vice president of Drug Repurposing at GVK BIO, said, “GVK BIO is well known for its rich and extensive biological, chemical and clinical databases. A marriage between computational algorithms, analytical capabilities and our custom curated databases along with proven drug discovery experience enables us to develop a multi-pronged approach resulting in higher success rates.”
 
Sreeni Devidas, vice president business development at GVK BIO, said, “GVK BIO has leveraged its expertise in Informatics to successfully build its Drug Repurposing Platform. The success with Takeda illustrates the value add that this approach brings to enhance the pipeline of our customers and collaborators.”